• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

八种 SARS-CoV-2 变体的交叉反应性合理预测了沙贝冠状病毒中的免疫原性聚类。

Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses.

机构信息

Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), WHO Collaborating Center for Standardization and Evaluation of Biologicals, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, 102629, Beijing, China.

Jiangsu Recbio Technology Co., Ltd., 215300, Taizhou, China.

出版信息

Signal Transduct Target Ther. 2022 Jul 27;7(1):256. doi: 10.1038/s41392-022-01123-7.

DOI:10.1038/s41392-022-01123-7
PMID:35896529
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9328627/
Abstract

A steep rise in Omicron reinfection cases suggests that this variant has increased immune evasion ability. To evaluate its antigenicity relationship with other variants, antisera from guinea pigs immunized with spike protein of SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs) were cross-tested against pseudotyped variants. The neutralization activity against Omicron was markedly reduced when other VOCs or VOIs were used as immunogens, and Omicron (BA.1)-elicited sera did not efficiently neutralize the other variants. However, a Beta or Omicron booster, when administered as the 4th dose 3-months after the 3rd dose of any of the variants, could elicit broad neutralizing antibodies against all of the current variants including Omicron BA.1. Further analysis with 280 available antigen-antibody structures and quantification of immune escape from 715 reported neutralizing antibodies provide explanations for the observed differential immunogenicity. Three distinct clades predicted using an in silico algorithm for clustering of sarbecoviruses based on immune escape provide key information for rational design of vaccines.

摘要

奥密克戎再感染病例的急剧上升表明,该变体增加了免疫逃逸能力。为了评估其与其他变体的抗原性关系,用 SARS-CoV-2 关注变体(VOCs)和感兴趣变体(VOIs)的刺突蛋白免疫的豚鼠抗血清对假型变体进行了交叉测试。当使用其他 VOCs 或 VOIs 作为免疫原时,针对奥密克戎的中和活性明显降低,并且奥密克戎(BA.1)诱导的血清不能有效地中和其他变体。然而,当在任何变体的第 3 剂后 3 个月作为第 4 剂给予 Beta 或奥密克戎增强剂时,可以引发针对所有当前变体(包括奥密克戎 BA.1)的广泛中和抗体。使用基于免疫逃逸的 SARS-CoV-2 聚类的计算算法进行的 280 个可用抗原-抗体结构的进一步分析和对 715 种报告中和抗体的免疫逃逸的量化提供了对观察到的差异免疫原性的解释。基于免疫逃逸的 SARS-CoV-2 聚类的计算算法预测了三个不同的进化枝,为疫苗的合理设计提供了关键信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e659/9329473/92350777decb/41392_2022_1123_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e659/9329473/befd1ae46304/41392_2022_1123_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e659/9329473/5e4dd4458b24/41392_2022_1123_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e659/9329473/1333465fbfc1/41392_2022_1123_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e659/9329473/b9e5ef8c3a34/41392_2022_1123_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e659/9329473/3537f4a46544/41392_2022_1123_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e659/9329473/92350777decb/41392_2022_1123_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e659/9329473/befd1ae46304/41392_2022_1123_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e659/9329473/5e4dd4458b24/41392_2022_1123_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e659/9329473/1333465fbfc1/41392_2022_1123_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e659/9329473/b9e5ef8c3a34/41392_2022_1123_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e659/9329473/3537f4a46544/41392_2022_1123_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e659/9329473/92350777decb/41392_2022_1123_Fig6_HTML.jpg

相似文献

1
Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses.八种 SARS-CoV-2 变体的交叉反应性合理预测了沙贝冠状病毒中的免疫原性聚类。
Signal Transduct Target Ther. 2022 Jul 27;7(1):256. doi: 10.1038/s41392-022-01123-7.
2
SARS-CoV-2 Omicron variant emerged under immune selection.SARS-CoV-2 奥密克戎变异株是在免疫选择压力下出现的。
Nat Microbiol. 2022 Nov;7(11):1756-1761. doi: 10.1038/s41564-022-01246-1. Epub 2022 Oct 4.
3
The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron.假型 SARS-CoV-2 变异株奥密克戎的显著免疫逃逸。
Emerg Microbes Infect. 2022 Dec;11(1):1-5. doi: 10.1080/22221751.2021.2017757.
4
Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines.由 COVID-19 mRNA 疫苗诱导的抗体对 SARS-CoV-2 变体的差异中和与抑制作用。
Nat Commun. 2022 Jul 27;13(1):4350. doi: 10.1038/s41467-022-31929-6.
5
Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2.天然发生的刺突突变影响 SARS-CoV-2 的感染性和免疫原性。
Cell Mol Immunol. 2022 Nov;19(11):1302-1310. doi: 10.1038/s41423-022-00924-8. Epub 2022 Oct 12.
6
Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron.人类针对 SARS-CoV-2 的抗体具有反复出现的 YYDRxG 基序,保留了对包括奥密克戎在内的关注变体的结合和中和能力。
Commun Biol. 2022 Jul 29;5(1):766. doi: 10.1038/s42003-022-03700-6.
7
A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.第四针奥密克戎 RBD 疫苗加强了对 vaccinated mice 中 SARS-CoV-2 变异株(包括 BA.1 和 BA.2)的广泛中和作用。
J Med Virol. 2022 Aug;94(8):3992-3997. doi: 10.1002/jmv.27811. Epub 2022 May 6.
8
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway.SARS-CoV-2 奥密克戎是一种具有改变的细胞进入途径的免疫逃逸变体。
Nat Microbiol. 2022 Aug;7(8):1161-1179. doi: 10.1038/s41564-022-01143-7. Epub 2022 Jul 7.
9
Omicron BA.1 Mutations in SARS-CoV-2 Spike Lead to Reduced T-Cell Response in Vaccinated and Convalescent Individuals.奥密克戎 BA.1 突变使 SARS-CoV-2 刺突蛋白减少,导致接种疫苗和康复个体的 T 细胞反应降低。
Viruses. 2022 Jul 19;14(7):1570. doi: 10.3390/v14071570.
10
An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern.一种 ACE2 阻断抗体可提供广泛的中和作用,并预防奥密克戎和其他关切的 SARS-CoV-2 变体。
Sci Immunol. 2022 Jul 29;7(73):eabp9312. doi: 10.1126/sciimmunol.abp9312.

引用本文的文献

1
Guinea Pigs Are Not a Suitable Model to Study Neurological Impacts of Ancestral SARS-CoV-2 Intranasal Infection.豚鼠并非研究祖先型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)鼻内感染对神经影响的合适模型。
Viruses. 2025 May 15;17(5):706. doi: 10.3390/v17050706.
2
Immunogenicity and Safety of Omicron-Containing Multivalent COVID-19 Vaccines in Unvaccinated and Previously Vaccinated Adults.含奥密克戎的多价新冠疫苗在未接种疫苗和既往接种过疫苗的成年人中的免疫原性和安全性
Vaccines (Basel). 2024 Sep 27;12(10):1109. doi: 10.3390/vaccines12101109.
3
Longitudinal Analysis of Humoral and Cellular Immune Response up to 6 Months after SARS-CoV-2 BA.5/BF.7/XBB Breakthrough Infection and BA.5/BF.7-XBB Reinfection.

本文引用的文献

1
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.BA.2.12.1、BA.4 和 BA.5 逃避奥密克戎感染诱导的抗体。
Nature. 2022 Aug;608(7923):593-602. doi: 10.1038/s41586-022-04980-y. Epub 2022 Jun 17.
2
Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2.奥密克戎 BA.1 对 BA.2 和 BA.3 SARS-CoV-2 的交叉中和作用。
Nat Commun. 2022 May 26;13(1):2956. doi: 10.1038/s41467-022-30580-5.
3
Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages.SARS-CoV-2 奥密克戎 BA.1、BA.1.1、BA.2 和 BA.3 亚谱系的抗体逃逸。
SARS-CoV-2 BA.5/BF.7/XBB突破性感染及BA.5/BF.7-XBB再次感染后长达6个月的体液免疫和细胞免疫反应的纵向分析
Vaccines (Basel). 2024 Apr 26;12(5):464. doi: 10.3390/vaccines12050464.
4
The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19.PHH-1V HIPRA 疫苗:抗击 COVID-19 疫苗接种策略的新工具。
Rev Esp Quimioter. 2023 Oct;36(5):507-515. doi: 10.37201/req/046.2023. Epub 2023 Jun 12.
5
High-throughput screening of spike variants uncovers the key residues that alter the affinity and antigenicity of SARS-CoV-2.刺突蛋白变体的高通量筛选揭示了改变新冠病毒亲和力和抗原性的关键残基。
Cell Discov. 2023 Apr 11;9(1):40. doi: 10.1038/s41421-023-00534-2.
6
Molecular Characterization and Selection of Indigenous SARS-CoV-2 Delta Variant for the Development of the First Inactivated SARS-CoV-2 Vaccine of Pakistan.用于开发巴基斯坦首款新冠病毒灭活疫苗的本土新冠病毒德尔塔变异株的分子特征分析与筛选
Vaccines (Basel). 2023 Mar 7;11(3):607. doi: 10.3390/vaccines11030607.
Cell Host Microbe. 2022 Aug 10;30(8):1077-1083.e4. doi: 10.1016/j.chom.2022.05.001. Epub 2022 May 8.
4
Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.评估 2 至 3 剂 BNT162b2 mRNA COVID-19 疫苗后针对 SARS-CoV-2 变异株的中和抗体反应。
JAMA Netw Open. 2022 May 2;5(5):e2210780. doi: 10.1001/jamanetworkopen.2022.10780.
5
Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.NVX-CoV2373(TAK-019)疫苗在健康日本成年人中的安全性和免疫原性:一项 I/II 期随机对照试验的中期报告。
Vaccine. 2022 May 26;40(24):3380-3388. doi: 10.1016/j.vaccine.2022.04.035. Epub 2022 Apr 29.
6
Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants.严重急性呼吸综合征冠状病毒2型奥密克戎BA.1和BA.2变体的中和作用
N Engl J Med. 2022 Apr 21;386(16):1579-1580. doi: 10.1056/NEJMc2201849. Epub 2022 Mar 16.
7
Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell-cell fusion, and neutralization sensitivity.分析 SARS-CoV-2 变体 B.1.617:宿主嗜性、蛋白水解激活、细胞-细胞融合和中和敏感性。
Emerg Microbes Infect. 2022 Dec;11(1):1024-1036. doi: 10.1080/22221751.2022.2054369.
8
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa.南非出现奥密克戎后,SARS-CoV-2 再感染的风险增加。
Science. 2022 May 6;376(6593):eabn4947. doi: 10.1126/science.abn4947.
9
Antibody evasion properties of SARS-CoV-2 Omicron sublineages.SARS-CoV-2 奥密克戎亚谱系的抗体逃逸特性。
Nature. 2022 Apr;604(7906):553-556. doi: 10.1038/s41586-022-04594-4. Epub 2022 Mar 3.
10
Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review.SARS-CoV-2 mRNA 疫苗接种后 6 个月体液免疫应答显著下降的特征:系统评价。
J Med Virol. 2022 Jul;94(7):2939-2961. doi: 10.1002/jmv.27688. Epub 2022 Mar 9.